in the technology
BUTYROSE® LSC® Microcaps
* RSPO License no. 9-1708-16-100-00
** the dye is present exclusively in the outer operculum
To best perform its functions – including promoting metabolic health with an eutrophic effect on the colon mucosa and bioregulating the intestinal flora – (see scientific papers), it is preferable that butyric acid is in the form linked to sodium due to its high lipophilicity and cell exchange capacity.
Sodium butyrate is a very active molecule but with a high degree of dissociation (pKa 4.82), which in the absence of adequate protection would not reach the intestine, in particular the colon / rectum.
This is why Butyrose® contains Sodium Butyrate LSC® microcaps: thanks to its patented formula (EU n.2352386), sodium butyrate is incorporated into a lipophilic microcapsule with LSC® -Lipophilic Spray Cooling- barrier effect technology, which it guarantees stability to the sodium-butyrate bond, a wide active surface and an extended diffusion capacity in the intestine, especially in the colon, where the bacterial concentration is greater.
Diarrhea, abdominal pain and general malaise – people with these symptoms may be in a condition in which intestinal inflammation is underway and the flora is altered.
In fact, the intestine is colonized by a rich population of bacteria that make up the so-called “intestinal flora” or “microbiota”. The alterations of the microbiota are: Eubiosis and Dysbiosis.
The first is the physiological condition characterized by a correct balance between the bacterial species that naturally colonize the intestine. The second refers to a condition of altered balance between the bacterial species that normally colonize the intestine.